Donor Blood Cell-based Platform
Unlike the commonly used αβ T cells that are restricted to autologous application only, γδ T cells may provide a potent “off-the-shelf” cytotoxic cell source to treat cancers in different recipients without causing graft-versus-host disease.
CytoMed’s donor blood cell-based CAR-γδ T cell technology
Industry-friendly features of our CAR-γδ T cell technology
Source of starting material
Collection of starting material
Method to introduce CAR
Scope of application